NMC
IRWD icon

Nine Masts Capital’s Ironwood Pharmaceuticals IRWD Stock Holding History

Nine Masts Capital’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-13,527
Closed -$47.5K – 235
2026
Q1 		$47.5K Buy
+13,527
New +$55.4K 0.01% 145

Other funds holding IRWD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Nine Masts Capital's IRWD Position: Q2 2026 in Review

Nine Masts Capital sold out of Ironwood Pharmaceuticals (IRWD) in Q2 2026, closing a stake of 13,527 shares — an estimated $47.5K sold.

Nine Masts Capital first reported a position in IRWD in Q1 2026 and held it in 1 quarter. The position peaked at $47.5K in Q1 2026. 212 funds tracked by Wall St. Rank hold IRWD as of Q2 2026.

  • Nine Masts Capital reported no remaining Ironwood Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Nine Masts Capital sold 13,527 Ironwood Pharmaceuticals shares in Q2 2026, an estimated $47.5K.
  • Nine Masts Capital first reported a position in Ironwood Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • Nine Masts Capital's Ironwood Pharmaceuticals position peaked at $47.5K in Q1 2026.
  • 212 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q2 2026.

Based on Nine Masts Capital's 13F filing for Q2 2026, filed 7 Aug 2026.